JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis
BackgroundJanus kinase (JAK) inhibitors have been approved for the treatment of several immune-mediated diseases (IMIDs) including rheumatoid arthritis (RA) and psoriatic arthritis and are in clinical trials for numerous other IMIDs. However, detailed studies investigating the effects of different J...
Main Authors: | Natalie Frede, Raquel Lorenzetti, Janika M Hüppe, Iga Janowska, Arianna Troilo, Marei-Theresa Schleyer, Ana C. Venhoff, Reinhard E. Voll, Jens Thiel, Nils Venhoff, Marta Rizzi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1087986/full |
Similar Items
-
A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
by: Dillon KAL
Published: (2021-06-01) -
Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
by: Dongfan Wei, et al.
Published: (2023-04-01) -
The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
by: Diqin Yan, et al.
Published: (2022-08-01) -
COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy
by: Mansoor Khaledi, et al.
Published: (2022-08-01) -
Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted
by: Maurizio Benucci, et al.
Published: (2022-09-01)